

Vaccinia Ig Ameliorates Eczema Vaccinatum in a Murine Model of Atopic Dermatitis

Journal of Investigative Dermatology advance online publication, 22 December 2011; doi:10.1038/jid.2011.409

TO THE EDITOR

Recent concern that vaccinia virus (VV) might be used as a bioterror weapon has led to contingency plans for mass vaccination; however, a major concern is that patients with atopic dermatitis (AD) are susceptible to eczema vaccinatum (EV), a complication of smallpox vaccination (Copeman and Banatvala, 1971; Boguniewicz and Leung, 2010). This has prompted the National Institutes of Health/National Institute of Allergy and Infectious Diseases to form the Atopic Dermatitis Vaccinia Network for EV research. In affected individuals, VV spreads through skin, resulting in large primary lesions and satellite lesions, and infects internal organs. Vaccinia Ig (VIG) has been used to prevent and treat EV in AD patients accidentally exposed to, or inoculated with, VV (Copeman and Banatvala, 1971; Goldstein *et al.*, 1975). Studies in the literature reveal a mean EV mortality rate of 4% in AD patients treated with VIG, compared with 5% and 40% in two studies of historical controls (Hopkins and Lane, 2004). Four controlled studies and one observational study reported promising results with the use of VIG to prevent smallpox in contacts of patients with documented smallpox (Hopkins and Lane, 2004). However, there have been no controlled trials to establish the efficacy of VIG in the prevention and treatment of EV in AD patients.

We previously reported that BALB/c mice inoculated with VV at sites of Th2-biased allergic skin inflammation elicited by epicutaneous (EC) ovalbumin (OVA) sensitization exhibit features of EV, including satellite lesions and VV dissemination (Oyoshi *et al.*, 2009). We used this mouse model to examine the

efficacy of VIG in attenuating EV. BALB/c mice were EC sensitized with OVA or saline over 7 weeks (49 days), then immediately inoculated with VV Western Reserve strain (ATCC, VR-1454) by skin scarification at the site of EC sensitization using 10^7 PFU per mouse, and euthanized 7 days later. OVA-sensitized mice were divided into four groups: three received a single intraperitoneal injection of 10 mg per mouse of polyclonal anti-VV Ig (ATCC, NR-2632) on day -1 , $+1$, or $+3$ of VV inoculation; a fourth group received on day -1 the same dose of control Ig (CIG) prepared in-house from donors never vaccinated with VV (Supplementary Figure S1 online). VV inoculation of CIG-treated mice in OVA-sensitized skin sites resulted in modest, but significant, weight loss compared with mice inoculated with VV at saline-exposed sites. All three groups of VIG-treated OVA-sensitized mice were protected against weight loss (Supplementary Figure S2 online). Mice injected with VIG at days -1 and $+1$, but not $+3$, developed significantly smaller primary lesions and lower numbers of satellite lesions compared with CIG-treated mice (Figure 1a–c). Quantitative PCR analysis of VV genomes demonstrated that all three groups of VIG-treated mice had significantly decreased viral loads in inoculated skin and internal organs compared with CIG-treated controls (Figure 1d). The reduction of satellite lesions in day $+1$ -treated mice is consistent with a previous study (Shearer *et al.*, 2005). The failure of day $+3$ VIG administration to affect skin lesions despite drastically reducing viral load suggests that delayed VIG treatment could have allowed greater early viral replication

resulting in more robust cutaneous inflammation.

VV-encoded epidermal growth factor and anti-apoptotic protein F1L promote cell survival (Postigo *et al.*, 2009), and VV antigens colocalize with proliferating keratinocytes (Fisher *et al.*, 2011). VV inoculation in OVA-sensitized skin resulted in a significant increase in epidermal thickness in CIG-treated mice (Figure 2a and b). This was inhibited by VIG treatment. IFN- γ inhibits (Combadiere *et al.*, 2004), whereas Th2 and Th17 cytokines promote, VV replication *in vivo* and *in vitro* (Howell *et al.*, 2006; Oyoshi *et al.*, 2009). OVA-sensitized skin of CIG-treated mice exhibited an intense infiltrate with neutrophils, and an increase in local mRNA expression of Th2 cytokines (IL-4 and IL-13), IL-17, with no significant change in IFN- γ (Figure 2c). Cellular infiltration at VV-inoculated sites, which was predominantly neutrophilic, was decreased more in mice treated with VIG at days -1 and $+1$, than day $+3$ (Figure 2a and b). All three groups of VIG-treated mice showed decreased levels of Th2 cytokines in VV-inoculated skin compared with CIG-treated mice, with no change in IFN- γ (Figure 2c). Mice treated with VIG at days -1 and $+1$, but not day $+3$, exhibited significantly decreased levels of IL-17 mRNA expression in VV-inoculated skin (Figure 2b). The failure of day $+3$ VIG-treated mice to decrease IL-17 levels correlates with the persistence of neutrophils and inflammatory lesions in their skin, and is consistent with IL-17 being critical for neutrophil infiltration in our EV model (Oyoshi *et al.*, 2009).

Splenocytes from all three groups of VIG-treated mice secreted significantly less IL-4, IL-13, IFN- γ , and IL-17 in response to VV stimulation compared with splenocytes from CIG-treated mice

Abbreviations: AD, atopic dermatitis; CIG, control Ig; EC, epicutaneous; EV, eczema vaccinatum; MVA, modified vaccinia virus Ankara; OVA, ovalbumin; VIG, vaccinia Ig; VV, vaccinia virus




Figure 1. Treatment with vaccinia Ig (VIG) decreases the size of primary lesions, the number of satellite lesions, and vaccinia virus (VV) dissemination caused by VV inoculation at the sites of allergic skin inflammation. (a–c) Primary and satellite lesions in BALB/c mice inoculated with VV in saline (Sal)- and ovalbumin (OVA)-sensitized skin (a), area of primary lesions (b), and number of satellite lesions (c) 7 days after VV inoculation. Mice were treated with control Ig (CIG) or VIG on day –1, +1, or +3 of VV inoculation. Polyclonal antivaccinia virus (immune globulin G, human), NR-2632, was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID. Dashed circles indicate primary lesions. Arrows indicate satellite lesions. Lesion sizes were analyzed using the NIH image software Image J. (d) Viral load in skin and internal organs. Viral genomes were quantified by real-time PCR as described previously (Oyoshi *et al.*, 2009). Columns and error bars represent mean and SEM ($n=5$ per group). One-way analysis of variance was used to determine statistical differences between groups. * $P<0.05$, ** $P<0.01$. EC, epicutaneous; NS, not significant.




Figure 2. Cytokine expression and histology of vaccinia virus (VV)-inoculated skin of mice treated with vaccinia Ig (VIG). (a) Representative hematoxylin and eosin-stained sections of VV inoculation sites. Bars = 100 µm ($\times 200$ magnification) or 25 µm ($\times 1,600$ magnification). Arrows indicate neutrophils. (b) Epidermal thickness. (c) Cytokine mRNA expression as fold induction relative to VV-inoculated saline-exposed skin. Cytokine expression in the skin was assessed by quantitative real-time PCR (Oyoshi *et al.*, 2009). One-way analysis of variance was used to determine statistical differences between groups. Columns and error bars represent mean and SEM ($n=5$ per group). * $P<0.05$, ** $P<0.01$. CIG, control Ig; EC, epicutaneous; NS, not significant; OVA, ovalbumin; Sal, saline.

($P<0.01$, Supplementary Figure S3a online). This is likely due to the decreased antigenic stimulation in

VIG-treated mice. However, the protective VV-specific IgG2a antibody response (Xu *et al.*, 2004) was compar-

able in all groups, indicating that VV-treated mice generated sufficient T-helper-cell activity to drive normal

IgG2a production (Supplementary Figure S3b online). In humans, VIG prophylaxis does not interfere with the vaccination reaction (Nanning, 1962).

Our results are in agreement with a recent study that used neutralizing human mAbs in VV-infected NC/Nga mice (Tomimori *et al.*, 2011). Several mechanisms may account for the efficacy of VIG in limiting viral spread. Direct neutralization of the virus is likely. The IgG Fc region in VV-VIG antigen-antibody complexes and anti-idiotypic-anti-VIG complexes might activate FcγR⁺ effector cells (e.g., macrophages and NK cells) to limit VV replication (Ballow, 2011). Further studies are needed to understand the precise mechanisms of action of VIG in attenuating EV.

The dose of VIG we used is equivalent to a dose of 500 mg kg⁻¹ in humans, which is close to the recommended dose for treatment of EV (400 mg kg⁻¹). Thus, our data suggest that VIG may be effective in preventing and treating EV. We recently showed that attenuated VV strain-modified vaccinia virus Ankara (MVA) protects mice inoculated with VV in OVA-sensitized skin from VV infection (Oyoshi *et al.*, 2011). A dual strategy of MVA immunization and VIG administration should be evaluated in preventing EV in patients with AD.

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by NIH grant HHSN272201000020C.

Michiko K. Oyoshi¹, Narayanaswamy Ramesh¹ and Raif S. Geha¹


¹Division of Immunology, Department of Pediatrics, Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
E-mail: raif.geha@childrens.harvard.edu

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at <http://www.nature.com/jid>


REFERENCES

- Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. *J Allergy Clin Immunol* 127:315–23
- Boguniewicz M, Leung DY (2010) Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol* 125:4–13
- Combadiere B, Boissonnas A, Carcelain G *et al.* (2004) Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. *J Exp Med* 199:1585–93
- Copeman PW, Banatvala JE (1971) The skin and vaccination against smallpox. *Br J Dermatol* 84:169–73
- Fisher RW, Reed JL, Snoy PJ *et al.* (2011) Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. *Clin Vaccine Immunol* 18:67–74
- Goldstein JA, Neff JM, Lane JM *et al.* (1975) Smallpox vaccination reactions, prophylaxis, and therapy of complications. *Pediatrics* 55:342–7
- Hopkins RJ, Lane JM (2004) Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. *Clin Infect Dis* 39:819–26
- Howell MD, Gallo RL, Boguniewicz M *et al.* (2006) Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. *Immunity* 24:341–8
- Nanning W (1962) Prophylactic effect of anti-vaccinia gamma-globulin against post-vaccinal encephalitis. *Bull World Health Organ* 27:317–24
- Oyoshi MK, Elkhail A, Kumar L *et al.* (2009) Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. *Proc Natl Acad Sci USA* 106:14954–9
- Oyoshi MK, Wang JY, Geha RS (2011) Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis. *J Allergy Clin Immunol* 128:890–2 e3
- Postigo A, Martin MC, Dodding MP *et al.* (2009) Vaccinia-induced epidermal growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to suppress cell death during infection. *Cell Microbiol* 11:1208–18
- Shearer JD, Siemann L, Gerkovich M *et al.* (2005) Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. *Antimicrob Agents Chemother* 49:2634–41
- Tomimori Y, Kawakami Y, McCausland MM *et al.* (2011) Protective murine and human monoclonal antibodies against eczema vaccinatum. *Antivir Ther* 16:67–75
- Xu R, Johnson AJ, Liggitt D *et al.* (2004) Cellular and humoral immunity against vaccinia virus infection of mice. *J Immunol* 172:6265–71




Supplemental Figure 1

Figure S1. Experimental design of VIG treatment using a murine model of EV. Mice were EC sensitized with OVA or saline for 7 weeks followed by inoculation of 10⁷ plaque forming units/mouse by skin scarification. Mice were sacrificed after 7 days of VV inoculation and examined for clinical responses, viral load, serum levels of VV antibodies and cytokine production as previously described (Oyoshi *et al.*, 2009). 10 mg/mouse vaccinia immunoglobulin (VIG) (equivalent to human dose 400 mg/kg body weight) or control immunoglobulin (CIG) were administered by intraperitoneal injection on day-1 (prophylaxis), +1 (immediate/early treatment), or +3 (delayed/late treatment) of VV inoculation.



Supplemental Figure 2

Figure S2. Treatment with VIG protects OVA-sensitized mice from weight loss caused by VV inoculation at the sites of allergic skin inflammation. % of weight change was calculated relative to day 0 VV inoculation. Error bars represent mean and SEM (n=5 per group). One-way ANOVA was used to determine statistical differences between groups and CIG-treated OVA-sensitized group. *p<0.05, **p<0.01.



Supplemental Figure 3

Figure S3: VV specific systemic immune responses in mice treated with VIG. **a.** VV-specific cytokine production by splenocytes following VV stimulation using VV infected A20 cells as described previously (Oyoshi *et al.*, 2009). **b.** Serum levels of VV-specific IgG2a antibody titers after 7 days of VV inoculation. VV-specific IgG2a levels were analyzed as described previously (Oyoshi *et al.*, 2009). Columns and error bars represent mean and SEM (n=5 per group). One-way ANOVA was used to determine statistical differences between groups. **p<0.01.